News
CERT
16.08
-2.37%
-0.39
Absci: 'AI' Tag Keeping Company Afloat While Searching For Right Formula
Seeking Alpha · 2d ago
Certara Breaks Below 200-Day Moving Average - Notable for CERT
NASDAQ · 3d ago
Weekly Report: what happened at CERT last week (0506-0510)?
Weekly Report · 5d ago
Analysts Offer Insights on Healthcare Companies: Certara (CERT), Exact Sciences (EXAS) and AbCellera Biologics (ABCL)
TipRanks · 05/10 05:52
Certara Analyst Maintains Hold Rating Amid Mixed Financial Performance and Strategic Developments
TipRanks · 05/10 05:39
Certara (CERT) Gets a Hold from Barclays
TipRanks · 05/08 10:07
Certara (CERT) Gets a Hold from JMP Securities
TipRanks · 05/08 05:46
Certara, Inc. Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended March 31, 2024
Press release · 05/08 05:22
CERT Stock Earnings: Certara Meets EPS, Beats Revenue for Q1 2024
Certara reported earnings per share of 10 cents for the first quarter of 2024. The company reported revenue of $96.65 million. This was 3.22% better than the analyst estimate of $93.64 million. Certara reported results for first quarter 2024.
Investorplace · 05/08 00:55
Certara, Inc. (CERT) Q1 Earnings Meet Estimates
NASDAQ · 05/07 22:40
Certara Non-GAAP EPS of $0.10 in-line, revenue of $96.7M beats by $3.07M
Non-GAAP EPS of $0.10 in-line, revenue of $96.7M beats by $3.07M. Shares -7.25% AH. Certara reiterates its 2024 outlook for $385 million to $400 million in revenue.
Seeking Alpha · 05/07 22:06
Certara Q1 2024 GAAP EPS $0.10, Inline, Sales $96.654M Beat $93.637M Estimate
Certara reported quarterly earnings of $0.10 per share. The company reported quarterly sales of $96.654 million. Sales beat the analyst consensus estimate of $93.637 million by 3.22%. The company's sales are up 7.04 percent from the same period last year.
Benzinga · 05/07 20:37
CERTARA INC - REITERATING ITS 2024 OUTLOOK
Reuters · 05/07 20:15
Weekly Report: what happened at CERT last week (0429-0503)?
Weekly Report · 05/06 09:23
Top ideas in vertical software with valuations over or below 50th percentile - Baird
First quarter earnings results for the vertical software industry group are tracking "lightly better than expected" Analysts have separated ideas in vertical software with valuations over or below 50th percentile of recent trading history. Some companies have seen guidance raises and outlooks largely unchanged for the year.
Seeking Alpha · 05/02 14:39
Weekly Report: what happened at CERT last week (0422-0426)?
Weekly Report · 04/29 09:24
Weekly Report: what happened at CERT last week (0415-0419)?
Weekly Report · 04/22 09:22
Look Under The Hood: IWS Has 13% Upside
NASDAQ · 04/19 11:01
Weekly Report: what happened at CERT last week (0408-0412)?
Weekly Report · 04/15 09:21
When Should You Buy Certara, Inc. (NASDAQ:CERT)?
Certara, Inc. (NASDAQ:CERT) saw a double-digit share price rise of over 10% in the past month. The mid-cap company is still trading at a fairly cheap price of $29.90 on the NASDAQGS. The company is expected to grow its profit by 81% over the next year. Its future growth is not fully reflected in the share price yet. This indicates a potential opportunity to buy CERT at a low price.
Simply Wall St · 04/11 12:49
More
Webull provides a variety of real-time CERT stock news. You can receive the latest news about Certara, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CERT
Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development in the global biopharmaceutical industry. It is focused on producing medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its customers include life sciences companies of all sizes along with contract research organizations, academic institutions, and global regulators. Its software and service are used by approximately 2,400 biopharmaceutical companies and academic institutions across 66 countries, including 38 of the top 40 biopharmaceutical companies. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, Netherlands, Philippines, Poland, Portugal, Spain, Switzerland, Egypt, and the United Kingdom.